TY - JOUR
T1 - A meta-analysis on allergen-specific immunotherapy using MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis
AU - Becker, Sven
AU - Zieglmayer, Petra
AU - Canto, Gabriela
AU - Fassio, Filippo
AU - Yong, Patrick
AU - Acikel, Cengizhan
AU - Raskopf, Esther
AU - Steveling-Klein, Esther Helen
AU - Allekotte, Silke
AU - Mösges, Ralph
N1 - Funding Information:
SB reports personal fees from Allergopharma, ALK, HAL Allergy, Thermo Fischer Scientific, Sanofi Genzyme, Novartis, Bristol Meyers Squibb, MSD, Mylan, grants and personal fees from Bencard, Storz GmbH, BRAIN AG outside the submitted work. PZ reports grants and personal fees from Alk Abello, grants and personal fees from Allergopharma, grants and personal fees from Allergy Therapeutics, personal fees from Bencard, grants from Biomay, grants from Calistoga, grants from GSK, grants and personal fees from HAL, grants and personal fees from Marinomed, personal fees from Leti, personal fees from Meda, personal fees from Merck, grants from MSD, personal fees from Novartis, grants from Ono, grants from Oxagen, grants from RespiVert, personal fees from Sigmapharm, grants and personal fees from Stallergenes, personal fees from Thermo Fisher Scientific, grants from VentirX, all outside the submitted work. GC has nothing to disclose. FF received personal fees from Allergy Therapeutics Italia. PY has nothing to disclose. EHSK reports personal grant from Bencard, travel support from ALK, personal grant from Vifor. CA has nothing to disclose. ER reports personal fees from Bayer and personal fees from Gesellschaft für Phytotherapie outside the submitted work. SA reports grants and personal fees from Lofarma, personal fees from Servier, personal fees from Hexal, personal fees from Friulchem, outside the submitted work. RM reports personal fees from ALK, grants from ASIT biotech, personal fees from allergopharma, personal fees from Allergy Therapeutics, grants and personal fees from Bencard, grants from Leti, grants, personal fees and non‐financial support from Lofarma, non‐financial support from Roxall, grants and personal fees from Stallergenes, grants from Optima, personal fees from Friulchem, personal fees from Hexal, personal fees from Servier, personal fees from Klosterfrau, non‐financial support from Atmos, personal fees from Bayer, non‐financial support from Bionorica, personal fees from FAES, personal fees from GSK, personal fees from MSD, personal fees from Johnson&Johnson, personal fees from Meda, personal fees and non‐financial support from Novartis, non‐financial support from Otonomy, personal fees from Pohl‐Boscamp, personal fees from Stada, personal fees from Hikma, personal fees from UCB, non‐financial support from Ferrero, grants from BitopAG, grants from Hulka, personal fees from Nuvo, grants from Ursapharm, outside the submitted work.
Funding Information:
We thank Lea Radtke for her help in translating the French articles. This meta‐analysis was funded by Bencard Allergie GmbH.
Publisher Copyright:
© 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
PY - 2021/6
Y1 - 2021/6
N2 - BACKGROUND: The World Allergy Organization and the European Academy of Allergy and Clinical Immunology recommend to perform product-specific meta-analyses for allergen-specific immunotherapies because of the high degree of heterogeneity between individual products. This meta-analysis evaluates the efficacy and safety of Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids (MATA).METHODS: The databases MEDLINE, LILACS, embase, LIVIVO, Web of Science and Google (Scholar) were searched for publications on MATA up to June 2019. Primary endpoint was the combined symptom and medication score (CSMS). Secondary endpoints were single scores, immunogenicity and improvement of allergic condition. Secondary safety endpoints were the occurrence of side effects. A random effects model was applied with (standardized) mean differences ([S]MDs) including confidence intervals (CI). Heterogeneity was analyzed using the I2 index and publication bias using Egger's test and Funnel plots. Subgroups were analyzed regarding age and asthma status.RESULTS: Eight randomized double-blind placebo-controlled trials were selected for efficacy and 43 publications for safety analysis. In total, 4531 patients were included in this analysis including eight studies containing data on children and adolescents. AIT with MATA significantly reduced allergic symptoms and medication use with a SMD for CSMS of -0.8 (CI: -1.24, -0.36) in comparison to placebo. Heterogeneity was moderate between the studies. The total symptom score (-1.2 [CI: -2.11, -0.29]) and the total medication score (-2.2 [CI: -3.65, -0.74]) were also significantly reduced after MATA treatment. Patient's condition improved significantly after treatment with MATA, with an odds ratio of 3.05 (CI: 1.90, 4.90) when compared to placebo. The proportion of patients, who developed side effects was 38% (CI: 19%, 57%). No serious side effects occurred. Safety in the subgroups of asthmatic patients, children and adolescents did not differ from the overall patient population.CONCLUSIONS: This meta-analysis reveals a large body of evidence from publications investigating MATA. MATA significantly improved allergic symptoms and reduced the use of anti-allergic medication in comparison to placebo, with an excellent safety profile. Especially for children and asthmatic patients, the use of MATAs can be considered as safe, because the safety profiles in these groups did not differ from the total patient population.
AB - BACKGROUND: The World Allergy Organization and the European Academy of Allergy and Clinical Immunology recommend to perform product-specific meta-analyses for allergen-specific immunotherapies because of the high degree of heterogeneity between individual products. This meta-analysis evaluates the efficacy and safety of Glutaraldehyde-modified and MCT® (MicroCrystalline Tyrosine)-adsorbed allergoids (MATA).METHODS: The databases MEDLINE, LILACS, embase, LIVIVO, Web of Science and Google (Scholar) were searched for publications on MATA up to June 2019. Primary endpoint was the combined symptom and medication score (CSMS). Secondary endpoints were single scores, immunogenicity and improvement of allergic condition. Secondary safety endpoints were the occurrence of side effects. A random effects model was applied with (standardized) mean differences ([S]MDs) including confidence intervals (CI). Heterogeneity was analyzed using the I2 index and publication bias using Egger's test and Funnel plots. Subgroups were analyzed regarding age and asthma status.RESULTS: Eight randomized double-blind placebo-controlled trials were selected for efficacy and 43 publications for safety analysis. In total, 4531 patients were included in this analysis including eight studies containing data on children and adolescents. AIT with MATA significantly reduced allergic symptoms and medication use with a SMD for CSMS of -0.8 (CI: -1.24, -0.36) in comparison to placebo. Heterogeneity was moderate between the studies. The total symptom score (-1.2 [CI: -2.11, -0.29]) and the total medication score (-2.2 [CI: -3.65, -0.74]) were also significantly reduced after MATA treatment. Patient's condition improved significantly after treatment with MATA, with an odds ratio of 3.05 (CI: 1.90, 4.90) when compared to placebo. The proportion of patients, who developed side effects was 38% (CI: 19%, 57%). No serious side effects occurred. Safety in the subgroups of asthmatic patients, children and adolescents did not differ from the overall patient population.CONCLUSIONS: This meta-analysis reveals a large body of evidence from publications investigating MATA. MATA significantly improved allergic symptoms and reduced the use of anti-allergic medication in comparison to placebo, with an excellent safety profile. Especially for children and asthmatic patients, the use of MATAs can be considered as safe, because the safety profiles in these groups did not differ from the total patient population.
UR - http://www.scopus.com/inward/record.url?scp=85108545517&partnerID=8YFLogxK
U2 - 10.1002/clt2.12037
DO - 10.1002/clt2.12037
M3 - Review article
C2 - 34523256
VL - 11
SP - e12037
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
SN - 2045-7022
IS - 4
M1 - e12037
ER -